scPharmaceuticals, Inc., based in Burlington, Massachusetts, focuses on developing subcutaneous pharmaceutical products like FUROSCIX for conditions such as congestive heart failure and infection treatments. The company, founded with 96 employees, went public in 2017 and prioritizes healthcare cost reduction and improved health outcomes.
scPharmaceuticals Inc (SCPH) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, scPharmaceuticals Inc's actual EPS was -$0.44, missing the estimate of -$0.41 per share, resulting in a -6.77% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
